This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023

InRange Study

Author: Sanofi

Editorial Team

  

Prescribing Information Toujeo (insulin glargine 300 units/mL)

toujeo logo
Sanofi is here to support you and your patients.

Ask us your questions about our products, patient materials or organising a meeting.

InRange Clinical Summary

InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo® and insulin degludec 100U/mL in people with T1DM.

Download this six page clinical summary about the InRange study and learn more about the study design, the key findings and more

InRange Study

Professor Richard Bergenstal presents the results of the InRange study. This study is the first randomised controlled trial to compare second generation basal insulin analogues Toujeo® and insulin degludec 100 U/mL. It compares adults with T1DM, using Time-in-Range (TIR) as the primary endpoint. Watch and learn about the study design and key findings.

Time in Range Guide

View the guide below to find out more about the impact of time in range on your patients. 

SEE MORE FROM SCIENCE

Toujeo

Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 

Patient Website

Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

Get in touch with the Diabetes Team

MAT-XU-2201545 (v5.0) Date of Preparation: October 2023

MAT-XU-2205633 (v4.0) Date of Preparation: October 2023